INTRODUCTION
Diagnosis of mastocytosis is frequently delayed given the variable clinical phenotypes at presentation. Here we present a case of a 64-year-old woman diagnosed with cutaneous mastocytosis (CM), specifically urticaria pigmentosa (UP), initially localized to an area treated with radiotherapy that subsequently progressed to indolent systemic mastocytosis (SM).
CASE REPORT
A 64-year-old woman had an 18-month history of a maculopapular telangiectatic rash on her right breast (Fig 1) . Darier sign was positive. She had no systemic symptoms and was otherwise well. The rash was first noticed 3 months after treatment for high-grade ductal carcinoma in situ with wide local excision, radiotherapy (50 Gy in 25 fractions), and anastrozole. A skin biopsy of the rash was performed and histopathologic findings were consistent with CM (Fig 2) , and considering the predominant maculopapular nature of the rash with only minimal telangiectasia, the diagnosis of UP was favored.
SM was excluded after hematologic review of computed tomography (CT) scans of the patient's neck, chest, abdomen, and pelvis; bone marrow aspirate and trephine (BMAT); and bone densitometry, all of which showed no evidence of extracutaneous involvement. There was no hepatosplenomegaly or lymphadenopathy, and PCR for c-KIT D816V mutation of BMAT was negative. The patient had no malabsorptive symptoms, no drug or other allergies, and no history of anaphylaxis. She was counseled in a dermatology clinic to avoid provoking factors and use antihistamines as necessary.
Over the following 5 years, the patient's rash progressively spread to include most of her torso. She developed systemic symptoms consistent with mast cell mediator release including hot flushes and erythema after showering. Her basal serum tryptase increased (Fig 3) . Repeat BMAT showed multifocal mast cell aggregates admixed with mature lymphocytes. More than 25% of her mast cells were spindle shaped with atypical morphology (Fig 4) . There was no morphologic evidence of associated clonal hematologic nonemast cell disease. PCR for c-KIT D816V mutation of BMAT was positive.
Restaged CT scan and bone densitometry scan were normal. Given the absence of B or C findings 1 used to classify clinical variants of SM, and the absence of a clonal hematologic nonemast cell disease, the patient was diagnosed with indolent 
DISCUSSION
Mastocytosis is a heterogeneous disease caused by accumulation of clonal mast cells within cutaneous and extracutaneous tissues. Patients have variable clinical phenotypes on the basis of mast cell skin infiltration patterns, mast celle mediator release, and mast cell organ infiltration and often require multidisciplinary management from dermatologists, immunologists, and hematologists. Owing in part to its rarity and the variable clinical phenotypes at presentation, the diagnosis of mastocytosis is delayed on average by 9 years. CM subclassification relies heavily on the clinical features of the rash, with the WHO recognizing 3 distinct CM entities. Some authors suggest a fourth subtype of CM, telangiectasia macularis eruptive perstans (TMEP), should be considered a distinct entity from UP. 3 In this case, in the context of recent radiotherapy to the biopsied area that could have increased both telangiectasia and reactive mast cell numbers, the differentials of UP, TMEP, and radiotherapy-induced telangiectasia were considered. Histopathologic stains showed a higher density of mast cells than what is typical for a subclassification of TMEP or radiotherapy-induced telangiectasia, and a diagnosis of UP was favored. Clinical features, in particular the predominant maculopapular nature of the rash with only minimal telangiectasia, were also in keeping with a diagnosis of UP.
Of interest was the close proximity of radiotherapy to the initial diagnosis of CM. CM localized to a radiation field has been reported twice previously, 4, 5 and in all cases followed breast cancer treatment. Whether radiotherapy has a direct role in pathogenesis, perhaps through acquisition of additional mutations in signaling pathways, epigenetic regulators, RNA splicing machinery, or transcription factors, is not clear. c-KIT D816V mutation burden does not correlate with clinical manifestations, mastocytosis subclassification, disease severity, or progression, 6 rather acquired mutations have been proposed to contribute to the variable symptomatology. 7 Identification of patients with SM is crucial, allowing the relevant subspecialty to optimally manage variable symptoms. The literature reports that 85%-90% of adult-onset mastocytosis are diagnosed with SM. However, a recent study showed that in adult-onset, biopsy-proven mastocytosis of the skin, 97% fulfill the WHO criteria for diagnosis of SM when using a highly sensitive molecular method involving microdissection of mast cells from bone marrow biopsy for c-KIT D816V PCR analysis, a technique not routinely available to diagnostic laboratories. Even of the remaining 3% who failed to meet the diagnostic WHO criteria for SM, rare dissected marrow mast cells (at \1% of total marrow cellularity) were positive for c-KIT D816V, challenging the concept and diagnosis of adultonset CM. 1 Considering that most diagnostic laboratories perform c-KIT D816V PCR on whole genomic DNA extracted from formalin-fixed and paraffinembedded bone marrow biopsies, a diagnosis of SM might be missed in 15% of cases that would have been met using microdissection of mast cells. Therefore, rather than our case representing evolution of CM to SM, it is likely that the patient had clonally aberrant mast cells present in the initial bone marrow biopsy with which routine c-KIT D816V testing was performed but not sensitive enough to detect. Importantly, this case highlights the need to be aware of the high likelihood of a diagnosis of SM in adult-onset mastocytosis of the skin, for which the clinical implications are substantial. Patients diagnosed with SM by using standard molecular techniques have a higher (up to 49%) cumulative risk of anaphylaxis 8 ; they are advised to carry an emergency adrenalin autoinjector (EpiPen, King Pharmaceuticals, Bristol, TN) and use precaution around operations and anesthetics, which can precipitate anaphylaxis. Furthermore, they require ongoing hematologic review to monitor for extracutaneous organ dysfunction, as well as for evolution to more aggressive forms of SM requiring systemic chemotherapy. Whether these increased risks pertain to SM with a low bone marrow burden of mast cell disease detected only using more sensitive molecular techniques remains to be determined.
